SEC Comment Letter for AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946) (AXIM) — May 19, 2021
AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946)
Date: May 19, 2021 · CIK: 0001514946 · Accession: 0000000000-21-006337
AI Filing Summary & Sentiment
File numbers found in text: 333-256162
Letter
United States securities and exchange commission logo May 19, 2021 John W. Huemoeller, II President AXIM Biotechnologies, Inc. 6191 Cornerstone Court, E. Suite 114 San Diego, CA 92121 Re:AXIM Biotechnologies, Inc. Registration Statement on Form S-1 Filed May 14, 2021 File No. 333-256162 Dear Mr. Huemoeller: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact David Gessert at 202-551-2326 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 19, 2021
John W. Huemoeller, II
President
AXIM Biotechnologies, Inc.
6191 Cornerstone Court, E. Suite 114
San Diego, CA 92121
Re:AXIM Biotechnologies, Inc.
Registration Statement on Form S-1
Filed May 14, 2021
File No. 333-256162
Dear Mr. Huemoeller:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact David Gessert at 202-551-2326 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences